Neostigmine Cooper (Neostigmine Methylsulfate)

Neostigmine methylsulfate, the active ingredient in Neostigmine Cooper, is a reversible anticholinesterase presented as an injectable solution for intramuscular, intravenous or subcutaneous use. It is employed to reverse non‑depolarizing neuromuscular blockade and to improve muscle strength in myasthenia gravis patients.

GNH USA supplies Neostigmine Cooper as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Neostigmine Cooper acts on the cholinergic neuromuscular pathway to restore acetylcholine activity. - Reversal of non‑depolarizing neuromuscular blockade: restores muscle strength after surgery using curare‑type relaxants. - Myasthenia gravis: enhances neuromuscular transmission to improve muscle weakness. - Anesthesia adjunct: facilitates recovery from muscle relaxants during general anesthesia.

Neostigmine may cause a range of cholinergic‑related reactions.

Common Side Effects: - Nausea and vomiting - Increased salivation and sweating - Abdominal cramps or diarrhea - Muscle fasciculations - Dizziness or headache

Serious or Rare Side Effects: - Bradycardia or severe hypotension - Bronchospasm or respiratory distress - Cholinergic crisis with muscle weakness - Allergic reactions including rash or anaphylaxis - Seizures or convulsions

Neostigmine requires careful monitoring due to its cholinergic activity. - Renal impairment: adjust dose and monitor for accumulation. - Asthma or COPD: watch for bronchospasm. - Bradyarrhythmias: avoid rapid administration. - Concomitant anticholinergic drugs: may mask symptoms of excess cholinergic activity. - Use with anticholinergic agents (e.g., atropine) to offset muscarinic side effects when needed. - Store at ambient temperature: keep in original container, protect from moisture and light.

Neostigmine can interact with other drugs that affect cholinergic transmission.

Major Interactions (Avoid): - Other reversible cholinesterase inhibitors: additive cholinergic effects may lead to toxicity. - Strong anticholinergic agents (e.g., atropine, scopolamine): may mask signs of cholinergic excess.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may potentiate bradycardia. - Respiratory depressant anesthetics: increased risk of respiratory compromise. - Diuretics: may alter electrolyte balance, influencing neuromuscular response.